secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2023-11-16T23:59:59+00:00
Accession:  0001140361-23-053659
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics expands license from Factor Bioscience, gains know-how and multi-tier sublicense rights
--------------------------------------------------------------------------------

- Amended & Restated Exclusive License Agreement dated Nov 14, 2023 expands Eterna's rights to include necessary know-how and multi-tier sublicensing.
- CEO Matthew Angel is co-founder, President, CEO and director of Factor's parent company, creating a related-party transaction.
- Licensor's termination rights are reduced; technology transfer to Eterna is now included subject to use restrictions.
- Original agreement was from Feb 20, 2023, amended July 12, 2023; this restatement replaces it entirely.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036123053659/0001140361-23-053659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036123053659/ef20014811_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-053659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer